115370 Results

People

  1. Ladanyi
    Ladanyi
  2. Motzer
    Motzer
  3. Reuter
    Reuter
  4. Scher
    Scher
  5. Brennan
    Brennan
  6. Giralt
    Giralt
  7. Gonen
    Gonen
  8. Perales
    Perales
  9. Hudis
    Hudis
  10. Jarnagin
    Jarnagin

Groups

  1. Department of Medicine (39031)
  2. GSK Faculty (22466)
  3. Solid Tumor Oncology Division (22055)
  4. Surgery (21246)
  5. Sloan Kettering Institute Faculty (16085)
  6. Survivorship Research (15761)
  7. Center for Hematologic Malignancies (13261)
  8. Hematologic Malignancies, Division of (13086)
  9. Sloan Kettering Institute Postdocs (12935)
  10. Department of Pathology and Laboratory Medicine (12608)
Formats
  1. Journal Article (66746)
  2. Meeting Abstract (33620)
  3. Book Section (5027)
  4. Review (3744)
  5. Editorial (2162)
  6. Conference Paper (1525)
  7. Correspondence (661)
  8. Guidelines (660)
  9. Research Letter (548)
  10. Miscellaneous (339)
  11. Book Whole (338)
Groups
  1. Department of Medicine (39031)
  2. GSK Faculty (22466)
  3. Solid Tumor Oncology Division (22055)
  4. Surgery (21246)
  5. Sloan Kettering Institute Faculty (16085)
  6. Survivorship Research (15761)

More Groups

People
  1. Marc Ladanyi (1326)
  2. Robert Motzer (1243)
  3. Victor Reuter (1228)
  4. Howard Scher (1130)
  5. Murray Brennan (1059)
  6. Sergio Giralt (1049)

More People

Years
  1. 2025 (1982)
  2. 2024 (5377)
  3. 2023 (5804)
  4. 2022 (6168)
  5. 2021 (5712)
  6. 2020 (5598)

More Years

Publications
  1. Journal of Clinical Oncology (8590)
  2. Blood (4950)
  3. Cancer Research (2701)
  4. International Journal of Radiation Oncology, Biology, Physics (2610)
  5. Laboratory Investigation (1879)
  6. Modern Pathology (1812)

More Publications

Publishers
  1. Elsevier Inc. (13855)
  2. American Society of Clinical Oncology (9157)
  3. Springer (7152)
  4. Nature Publishing Group (6367)
  5. American Association for Cancer Research (6002)
  6. Elsevier Science, Inc. (5503)

More Publishers

Results (115370)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 1, first-in-human, dose-escalation and expansion study of FX-909 in patients with advanced solid malignancies, including advanced urothelial carcinoma
    Meeting Abstract

    Iyer, G.; Gao, X.; Rasco, D. W.; Milowsky, M. I.; Garmezy, B.; Rivera, I. I. R.; Tepper, J.; Moles, M. A.; Gjini, E.; Bowden, M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • PRECISION 1: A phase 2, multicenter, open-label basket trial of <i>nab</i>-sirolimus for malignant solid tumors harboring pathogenic inactivating alterations in TSC1 and TSC2
    Meeting Abstract

    Iyer, G.; Kwiatkowski, D. J.; Ding, L.; Schmid, A. N.; Navarro, W. H.; Ahnert, J. R.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • AMBASSADOR Alliance A031501: Phase III randomized adjuvant study of pembrolizumab in muscle-invasive and locally advanced urothelial carcinoma (MIUC) vs observation
    Meeting Abstract

    Apolo, A. B.; Ballman, K. V.; Sonpavde, G. P.; Berg, S. A.; Kim, W. Y.; Parikh, R. A.; Teo, M. Y.; Sweis, R. F.; Geynisman, D. M.; Grivas, P.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • ARAMON: A phase 2, randomized, open-label study comparing darolutamide (DARO) vs enzalutamide (ENZA) monotherapy on serum testosterone levels in patients (pts) with castration-sensitive prostate cancer (CSPC) after biochemical recurrence (BCR)
    Meeting Abstract

    Laccetti, A. L.; Smith, M. R.; Scher, H. I.; Verholen, F.; Adorjan, P.; Dissanayake, M.; Gao, X.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Apalutamide (APA) plus intermittent versus continuous androgen-deprivation therapy (ADT) in participants (pts) with metastatic castration-sensitive prostate cancer (mCSPC): LIBERTAS phase 3 study design
    Meeting Abstract

    Azad, A.; Badillo, M. A.; Dong, Q.; Morgans, A. K.; Rathkopf, D. E.; Runcie, K.; Zhang, T.; Pruthi, R.; Bhaumik, A.; Mundle, S.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Enfortumab vedotin (EV) in combination with pembrolizumab (P) versus chemotherapy in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC): Subgroup analyses results from EV-302, a phase 3 global study
    Meeting Abstract

    Van der Heijden, M. S.; Powles, T.; Gupta, S.; Bedke, J.; Kikuchi, E.; De Wit, R.; Galsky, M. D.; Duran, I.; Necchi, A.; Retz, M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Adjuvant nivolumab monotherapy vs placebo for localized renal cell carcinoma at high risk of relapse after nephrectomy: Results from Part B of the randomized, phase 3 CheckMate 914 trial
    Meeting Abstract

    Motzer, R. J.; Bex, A.; Russo, P.; Tomita, Y.; Cutuli, H.; Rojas, C.; Gross-Goupil, M.; Schinzari, G.; Melichar, B.; Barthelemy, P.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Analysis of inactivating TSC1 and TSC2 alterations in advanced genitourinary (GU) cancers from a real-world patient population in the Foundation Medicine genomic database
    Meeting Abstract

    Iyer, G.; Palma, N. A.; Navarro, W. H.; Kwiatkowski, D. J.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Clinical and molecular characterization of urothelial (UC) vs. small cell carcinoma (SCC) of the urinary tract
    Meeting Abstract

    Chawla, N. S.; Mercier, B. D.; Govindarajan, A.; Li, X.; Castro, D. V.; Ebrahimi, H.; Barragan-Carrillo, R.; Zang, P. D.; Levee, A. A.; Dizman, N.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Impact of insurance payer status (IS) on practice patterns and overall survival (OS) in patients (pts) with metastatic urothelial carcinoma (mUC)
    Meeting Abstract

    Mercier, B. D.; Tripathi, N.; Govindarajan, A.; Gebrael, G.; Narang, A.; Li, X.; Castro, D. V.; Chehrazi-Raffle, A.; Dizman, N.; Ebrahimi, H.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save